Literature DB >> 6544903

Different ways to modify monoclonal antibodies.

G Köhler, B Baumann, A Iglesias, J McCubrey, M J Potash, A Traunecker, D Zhu.   

Abstract

In this paper we summarize experiments which were undertaken to create altered antibody molecules. Three different approaches were used. Established hybridoma lines were re-hybridized to mouse spleen cells to generate arrays of secondary hybridomas which express one particular heavy chain and one specificity together with a multitude of different light chains. In such hybrids the influence of light chains to the antibody combining site and the influence of affinity to antibody effector functions can be studied. Another way to obtain altered antibodies was the selection of cells producing less lytic IgM. With this technique we obtained (among many other variants) a series of mu-deletion products which were used to map the fine specificity of rat anti-mouse mu monoclonal antibodies. Both the anti-mu antibodies and the deletion variants were used to assign the Clq binding to the fourth C mu-domain demonstrating the power of mutant IgM in the structure-function analysis. In a third series of experiments we show the feasibility of generating new antibody combining sites by the methods of molecular genetics. The variable region gene of a heavy chain was placed in front of a kappa-constant region gene. The plasmid construct was transferred into mouse myeloma lines which stably express a variable heavy-constant light chain protein. Upon fusion with a light chain producing line, chimaeric light chain dimers with a functional antibody combining site were secreted. These experiments demonstrate that new series of man-made antibody molecules can be made in the future.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6544903     DOI: 10.1007/bf02934528

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  31 in total

1.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Authors:  J F Kearney; A Radbruch; B Liesegang; K Rajewsky
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

2.  A monoclonal antibody for large-scale purification of human leukocyte interferon.

Authors:  D S Secher; D C Burke
Journal:  Nature       Date:  1980-06-12       Impact factor: 49.962

3.  Secretion of a lambda 2 immunoglobulin chain is prevented by a single amino acid substitution in its variable region.

Authors:  G E Wu; N Hozumi; H Murialdo
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

4.  Expression of a VHC kappa chimaeric protein in mouse myeloma cells.

Authors:  J Sharon; M L Gefter; T Manser; S L Morrison; V T Oi; M Ptashne
Journal:  Nature       Date:  1984 May 24-30       Impact factor: 49.962

5.  Isolation of variants of mouse myeloma X63 that express changed immunoglobulin class.

Authors:  A Radbruch; B Liesegang; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

6.  Mutations affecting the structure and function of immunoglobulin M.

Authors:  M J Shulman; C Heusser; C Filkin; G Köhler
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

7.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  Identification and chemical synthesis of a tandemly repeated immunogenic region of Plasmodium knowlesi circumsporozoite protein.

Authors:  G N Godson; J Ellis; P Svec; D H Schlesinger; V Nussenzweig
Journal:  Nature       Date:  1983 Sep 1-7       Impact factor: 49.962

9.  Recombination between antibody heavy chain variable-region genes: evidence for gene conversion.

Authors:  U Krawinkel; G Zoebelein; M Brüggemann; A Radbruch; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

10.  Deletions in immunoglobulin mu chains.

Authors:  G Köhler; M J Potash; H Lehrach; M J Shulman
Journal:  EMBO J       Date:  1982       Impact factor: 11.598

View more
  3 in total

1.  Antibody domain mutants demonstrate autonomy of the antigen binding site.

Authors:  T Simon; K Rajewsky
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

2.  Derivation and diversification of monoclonal antibodies.

Authors:  G Köhler
Journal:  EMBO J       Date:  1985-06       Impact factor: 11.598

3.  Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells.

Authors:  A Traunecker; A Lanzavecchia; K Karjalainen
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.